Korylan

Paracetamol and Codeine Phosphate Hemihydrate, the active ingredient in Korylan, is a combination analgesic presented as an oral tablet for oral use. It is indicated for the relief of mild to moderate pain and the reduction of fever in adult patients.

GNH USA supplies Korylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Korylan, a combination analgesic, is employed across several common pain‑related conditions and febrile states.

- Mild to moderate pain: provides effective analgesia for everyday aches. - Fever: lowers elevated body temperature. - Post‑operative discomfort: assists in managing surgical pain. - Dental pain: alleviates discomfort after dental procedures. - Musculoskeletal pain: eases aches associated with strains or sprains. - Headache: reduces intensity of tension‑type headaches.

Korylan may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea - Constipation - Dizziness - Drowsiness - Vomiting - Sweating

Serious or Rare Side Effects: - Respiratory depression - Severe allergic reaction (anaphylaxis) - Hepatic injury - Dependence or addiction - Marked hypotension - Seizures (rare)

Before prescribing Korylan, clinicians should consider several safety factors.

- Liver function: assess hepatic status, especially in patients with chronic liver disease. - Renal function: evaluate kidney health, as metabolites are renally excreted. - Respiratory conditions: avoid in patients with severe respiratory depression or uncontrolled asthma. - Concomitant CNS depressants: use caution when combined with alcohol, benzodiazepines, or other opioids. - Dependence risk: monitor for signs of misuse or addiction. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Korylan can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Other opioid analgesics: additive risk of respiratory depression. - Benzodiazepines: increased sedation and respiratory compromise. - Alcohol: enhanced central nervous system depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may reduce conversion of codeine to morphine, lowering analgesic effect. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may decrease overall efficacy. - Anticholinergic agents: may exacerbate constipation. - Diuretics: can increase the likelihood of hypotension.